Examkin

Question

Difficulty: MediumPharmacokinetic and Pharmacodynamic Principles

A 45-year-old man presents to the clinic complaining of a severe headache, tremors, and decreased urine output over the past two days. His medical history is significant for a deceased-donor renal transplant two years ago for IgA nephropathy. His daily medications include tacrolimus, mycophenolate mofetil, and prednisone. Eight days ago, he was evaluated at an urgent care center for a respiratory tract infection and was prescribed a 7-day course of clarithromycin. Today, his blood pressure is 165/95 mmHg, compared to 120/75 mmHg at his last visit. Laboratory studies show a serum creatinine of 2.2 mg/dL, elevated from his baseline of 1.1 mg/dL. Which of the following pharmacokinetic alterations regarding the patient's immunosuppressive regimen most likely occurred?

  1. Decreased systemic clearance resulting in a prolonged elimination half-lifeAnswer
  2. B
    Upregulation of hepatic biotransformation pathways leading to a subtherapeutic steady-state concentration
  3. C
    Alteration in plasma protein binding leading to a higher concentration of the pharmacologically active unbound drug
  4. D
    Inhibition of active tubular secretion resulting in reduced renal elimination
  5. E
    Inhibition of intestinal P-glycoprotein resulting in an expanded apparent volume of distribution

Answer

Decreased systemic clearance resulting in a prolonged elimination half-life
Clarithromycin is a potent macrolide antibiotic that strongly inhibits the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is a calcineurin inhibitor with a narrow therapeutic index that relies heavily on CYP3A4 for its hepatic metabolism. The addition of a strong CYP3A4 inhibitor significantly decreases the systemic clearance (ClCl) of tacrolimus. According to the foundational pharmacokinetic relationship t1/2=0.693×VdClt_{1/2} = \frac{0.693 \times Vd}{Cl}, a reduction in systemic clearance leads to a proportionally prolonged elimination half-life (t1/2t_{1/2}). This disruption results in elevated steady-state serum concentrations, manifesting clinically as calcineurin-inhibitor toxicity (e.g., acute kidney injury, new-onset or worsening hypertension, neurotoxicity such as tremors and headache).

Step-by-Step Solution

1
Identify the critical drug interaction in the vignette.
The patient is taking tacrolimus (a calcineurin inhibitor) and was recently prescribed clarithromycin (a macrolide antibiotic).
Recognizing interacting drug classes is the first step in diagnosing medication-induced adverse events.
2
Determine the pharmacokinetic mechanism of the interaction.
Clarithromycin is a strong inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system. Tacrolimus is extensively metabolized by CYP3A4.
Understanding the metabolic pathways of narrow therapeutic index drugs is required to predict kinetic alterations.
3
Apply pharmacokinetic formulas to determine the clinical outcome.
Inhibiting CYP3A4 decreases the clearance (ClCl) of tacrolimus. Using the formula t1/2=0.693×VdClt_{1/2} = \frac{0.693 \times Vd}{Cl}, a decrease in clearance directly results in a prolonged half-life (t1/2t_{1/2}), leading to drug accumulation and nephrotoxicity (AKI, hypertension).
Linking enzymatic activity to standard kinetic variables confirms the exact physiological alteration.

Key Concept

Pharmacokinetic drug interactions via CYP3A4 inhibition
Rate this question

Topics

Pharmacokinetic and Pharmacodynamic Principles

More questions from this topic